Literature DB >> 22326483

Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease.

Renata P Lerner1, Luz Del Carmen G Trejo Martinez, Chunni Zhu, Marie-Françoise Chesselet, Miriam A Hickey.   

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disease characterized by progressive atrophy of the striatum, cerebral cortex, and white matter tracks. Major pathological hallmarks of HD include neuronal loss, primarily in the striatum, and dendritic anomalies in surviving striatal neurons. Although many mouse models of HD have been generated, their success at reproducing all pathological features of the disease is not fully known. Previously, we demonstrated extensive striatal neuronal loss and striatal atrophy at 20-26 months of age in a knock-in (KI) mouse model of HD. To further investigate this model, which carries a human exon 1 with ∼119 CAG repeats inserted into the mouse gene (initially 140 repeats), we have examined whether these mice exhibit the atrophy and neuronal anomalies characteristic of HD. Stereological analyses revealed no changes in the striatal volume of male and female homozygote mice at 4 months, however striatal atrophy was already present at 12 months in both sexes. Analysis of cortical and corpus callosum volume in male homozygotes revealed a loss in corpus callosum volume by 20-26 months. At this later age, the surviving striatal neurons displayed extensive loss of spines in distal branch orders that affected both immature and mature spines. Mirroring late stage HD striatal neuronal morphology, the striatal neurons at this late age also showed reduced dendritic complexity, as revealed by Sholl analysis. Tyrosine hydroxylase immunoreactivity was also decreased in the striatum of 20-26 month old KI mice, suggesting an alteration in striatal inputs. These data further indicate that CAG140 homozygote KI mice exhibit HD-like pathological features and are a useful model to test the effects of early and/or sustained administration of novel neuroprotective treatments.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22326483      PMCID: PMC3319635          DOI: 10.1016/j.brainresbull.2012.01.012

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  48 in total

1.  Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice.

Authors:  G J Klapstein; R S Fisher; H Zanjani; C Cepeda; E S Jokel; M F Chesselet; M S Levine
Journal:  J Neurophysiol       Date:  2001-12       Impact factor: 2.714

2.  Alterations in dopaminergic receptors in Huntington's disease.

Authors:  T D Reisine; J Z Fields; L Z Stern; P C Johnson; E D Bird; H I Yamamura
Journal:  Life Sci       Date:  1977-10-15       Impact factor: 5.037

3.  In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Bin Tang; Alexandre Kuhn; SoongHo Kim; Daniel H Geschwind; Timothy B Brown; Ruth Luthi-Carter; Michelle E Ehrlich
Journal:  Hum Mol Genet       Date:  2010-12-20       Impact factor: 6.150

4.  Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.

Authors:  M A Hickey; A Kosmalska; J Enayati; R Cohen; S Zeitlin; M S Levine; M-F Chesselet
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

5.  Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum.

Authors:  S J Kish; K Shannak; O Hornykiewicz
Journal:  Ann Neurol       Date:  1987-09       Impact factor: 10.422

6.  Evidence of a breakdown of corticostriatal connections in Parkinson's disease.

Authors:  B Stephens; A J Mueller; A F Shering; S H Hood; P Taggart; G W Arbuthnott; J E Bell; L Kilford; A E Kingsbury; S E Daniel; C A Ingham
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

7.  Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.

Authors:  Michael A Johnson; Vignesh Rajan; Charles E Miller; R Mark Wightman
Journal:  J Neurochem       Date:  2006-03-29       Impact factor: 5.372

8.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.

Authors:  Sarah J Tabrizi; Douglas R Langbehn; Blair R Leavitt; Raymund Ac Roos; Alexandra Durr; David Craufurd; Christopher Kennard; Stephen L Hicks; Nick C Fox; Rachael I Scahill; Beth Borowsky; Allan J Tobin; H Diana Rosas; Hans Johnson; Ralf Reilmann; Bernhard Landwehrmeyer; Julie C Stout
Journal:  Lancet Neurol       Date:  2009-07-29       Impact factor: 44.182

9.  Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Liliana B Menalled; Jessica D Sison; Ioannis Dragatsis; Scott Zeitlin; Marie-Françoise Chesselet
Journal:  J Comp Neurol       Date:  2003-10-06       Impact factor: 3.215

10.  Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease.

Authors:  Xiaofeng Gu; Véronique M André; Carlos Cepeda; Shi-Hua Li; Xiao-Jiang Li; Michael S Levine; X William Yang
Journal:  Mol Neurodegener       Date:  2007-04-30       Impact factor: 14.195

View more
  22 in total

1.  Increased Olfactory Bulb BDNF Expression Does Not Rescue Deficits in Olfactory Neurogenesis in the Huntington's Disease R6/2 Mouse.

Authors:  Shamayra Smail; Dalbir Bahga; Brittnee McDole; Kathleen Guthrie
Journal:  Chem Senses       Date:  2016-01-18       Impact factor: 3.160

2.  Cortical Network Dynamics Is Altered in Mouse Models of Huntington's Disease.

Authors:  Elissa J Donzis; Ana María Estrada-Sánchez; Tim Indersmitten; Katerina Oikonomou; Conny H Tran; Catherine Wang; Shahrzad Latifi; Peyman Golshani; Carlos Cepeda; Michael S Levine
Journal:  Cereb Cortex       Date:  2020-04-14       Impact factor: 5.357

3.  Loss-of-Huntingtin in Medial and Lateral Ganglionic Lineages Differentially Disrupts Regional Interneuron and Projection Neuron Subtypes and Promotes Huntington's Disease-Associated Behavioral, Cellular, and Pathological Hallmarks.

Authors:  Mark F Mehler; Jenna R Petronglo; Eduardo E Arteaga-Bracho; Maria E Gulinello; Michael L Winchester; Nandini Pichamoorthy; Stephen K Young; Christopher D DeJesus; Hifza Ishtiaq; Solen Gokhan; Aldrin E Molero
Journal:  J Neurosci       Date:  2019-01-09       Impact factor: 6.167

Review 4.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

5.  Dendritic spine instability leads to progressive neocortical spine loss in a mouse model of Huntington's disease.

Authors:  Reena Prity Murmu; Wen Li; Anthony Holtmaat; Jia-Yi Li
Journal:  J Neurosci       Date:  2013-08-07       Impact factor: 6.167

6.  Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease.

Authors:  Tim Indersmitten; Conny H Tran; Carlos Cepeda; Michael S Levine
Journal:  J Neurophysiol       Date:  2015-02-11       Impact factor: 2.714

7.  A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Authors:  Danielle A Simmons; Nadia P Belichenko; Tao Yang; Christina Condon; Marie Monbureau; Mehrdad Shamloo; Deqiang Jing; Stephen M Massa; Frank M Longo
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

8.  Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice.

Authors:  Y P Deng; T Wong; C Bricker-Anthony; B Deng; A Reiner
Journal:  Neurobiol Dis       Date:  2013-08-19       Impact factor: 5.996

9.  Cholinergic interneurons in the Q140 knockin mouse model of Huntington's disease: Reductions in dendritic branching and thalamostriatal input.

Authors:  Yun-Ping Deng; Anton Reiner
Journal:  J Comp Neurol       Date:  2016-06-06       Impact factor: 3.215

10.  Thiazolidinediones promote axonal growth through the activation of the JNK pathway.

Authors:  Rodrigo A Quintanilla; Juan A Godoy; Ivan Alfaro; Deny Cabezas; Rommy von Bernhardi; Miguel Bronfman; Nibaldo C Inestrosa
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.